PROCEPT BioRobotics (NASDAQ:PRCT) Earns Market Perform Rating from Oppenheimer

PROCEPT BioRobotics (NASDAQ:PRCT)‘s stock had its “market perform” rating restated by stock analysts at Oppenheimer in a research note issued on Thursday, Marketbeat reports.

Other equities analysts also recently issued reports about the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Thursday, January 22nd. Truist Financial dropped their target price on PROCEPT BioRobotics from $50.00 to $47.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Wall Street Zen raised PROCEPT BioRobotics from a “sell” rating to a “hold” rating in a research note on Saturday, January 10th. Morgan Stanley decreased their price target on PROCEPT BioRobotics from $56.00 to $51.00 and set an “overweight” rating for the company in a research note on Tuesday, December 2nd. Finally, Leerink Partners restated an “outperform” rating and set a $55.00 price objective on shares of PROCEPT BioRobotics in a report on Wednesday, November 5th. Eight research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $41.90.

PROCEPT BioRobotics Stock Performance

NASDAQ:PRCT opened at $22.69 on Thursday. The firm has a market capitalization of $1.27 billion, a PE ratio of -13.27 and a beta of 0.99. The stock’s fifty day moving average is $30.00 and its 200 day moving average is $33.53. PROCEPT BioRobotics has a fifty-two week low of $19.35 and a fifty-two week high of $66.85. The company has a debt-to-equity ratio of 0.14, a quick ratio of 7.20 and a current ratio of 8.44.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.21). PROCEPT BioRobotics had a negative return on equity of 24.82% and a negative net margin of 31.02%.The firm had revenue of $76.38 million for the quarter, compared to analysts’ expectations of $93.70 million. During the same period in the previous year, the firm earned ($0.35) earnings per share. The firm’s quarterly revenue was up 11.9% compared to the same quarter last year. On average, sell-side analysts anticipate that PROCEPT BioRobotics will post -1.75 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of PRCT. Advisory Services Network LLC increased its holdings in PROCEPT BioRobotics by 1.3% during the 2nd quarter. Advisory Services Network LLC now owns 20,109 shares of the company’s stock worth $1,158,000 after purchasing an additional 250 shares during the period. Vega Investment Solutions grew its position in shares of PROCEPT BioRobotics by 52.0% during the 2nd quarter. Vega Investment Solutions now owns 775 shares of the company’s stock worth $45,000 after buying an additional 265 shares in the last quarter. Frank Rimerman Advisors LLC increased its stake in shares of PROCEPT BioRobotics by 0.3% during the third quarter. Frank Rimerman Advisors LLC now owns 122,389 shares of the company’s stock valued at $4,368,000 after buying an additional 307 shares during the period. RiverPark Advisors LLC raised its holdings in shares of PROCEPT BioRobotics by 22.5% in the second quarter. RiverPark Advisors LLC now owns 1,761 shares of the company’s stock valued at $101,000 after acquiring an additional 324 shares in the last quarter. Finally, Osaic Holdings Inc. raised its holdings in shares of PROCEPT BioRobotics by 20.3% in the second quarter. Osaic Holdings Inc. now owns 2,001 shares of the company’s stock valued at $115,000 after acquiring an additional 337 shares in the last quarter. Institutional investors own 89.46% of the company’s stock.

Key PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Company outlined a multi‑year plan and issued 2026 guidance of $390M–$410M, signaling a path to higher revenue as it pursues pricing discipline and commercial realignment; the investor day attempted to frame a roadmap to sustainable growth. PROCEPT outlines $390M–$410M revenue target for 2026
• Positive Sentiment: Certain sell‑side firms maintained constructive ratings (buy/overweight/outperform) even after trimming targets, which leaves upside scenarios if execution and revenue recovery accelerate. Analyst updates (summary)
• Neutral Sentiment: Q4 results showed revenue grew ~11.9% YoY and gross profit improved, and operating and net losses narrowed versus a year ago — a mixed quarter that demonstrates progress but also falling short of market expectations. Q4 earnings highlights
• Neutral Sentiment: Investor‑day materials and the earnings call transcript provide detail on assumptions behind guidance and the commercial reset; these are useful for modeling recovery timing but don’t eliminate execution risk. Investor Day slideshow
• Negative Sentiment: EPS and revenue missed consensus (EPS -$0.53 vs. -$0.32 estimate; revenue below forecasts), which triggered immediate downward pressure as investors re‑priced near‑term growth expectations. Q4 miss coverage
• Negative Sentiment: Several analysts cut price targets and/or downgraded the stock (examples: Jefferies to Hold; BofA to Underperform with $20 PT; Leerink, TD Cowen and Piper lowered targets), increasing short‑term downside risk and contributing to weaker sentiment. Analyst downgrades and price target changes
• Negative Sentiment: A securities‑fraud investigation by Ademi LLP into PROCEPT’s disclosures emerged, adding legal and headline risk that can prolong volatility and deter risk‑tolerant buyers. Ademi LLP investigation notice
• Negative Sentiment: Shares reached a new 52‑week low and traded at elevated volumes around these announcements, reflecting broad selling pressure and a reassessment of near‑term execution and guidance credibility. 52-week low coverage

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.